To determine the direct effects of morning light intensity on postprandial glucose and lipid metabolism and metabolic gene expression in adipose tissue.
ID
Source
Brief title
Condition
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Postprandial glucose excursions, and expression of metabolic genes in adipose
tissue.
Secondary outcome
postprandial insulin excursions
- postprandial free fatty acid (FFA) excursions
- postprandial triglyceride levels
- morning glucocorticoid increase
- morning salivary melatonin decrease
- resting energy expenditure (REE)
- measurements of autonomic balance:
- skin temperature decrease
- heart rate variability
Background summary
Type 2 diabetes is a major threat to human health. Interestingly, the incidence
of obesity and type 2 diabetes correlates to the presence of artificial light.
Light for the non-visual system is detected in the retina by specialised
intrinsically photosensitive retinal ganglion cells (ipRGCs) that communicate
directly to various hypothalamic areas, and thereby modulate hormonal secretion
and autonomic activity. Light has time dependent autonomic effects in humans,
and administration of a light pulse to rats directly alters metabolic gene
expression in the liver. In this pilot study, we aim to determine if light
directly influences human glucose metabolism. We hypothesize that morning
bright light exposure decreases postprandial glucose excursions.
Study objective
To determine the direct effects of morning light intensity on postprandial
glucose and lipid metabolism and metabolic gene expression in adipose tissue.
Study design
cross-over intervention study
Intervention
Subjects enter the facility in the evening. They will remain in normal room
light (100-200 lux) for 4 hours. They receive a standard meal 2 hrs before
bedtime. They sleep for 8 hrs in the dark (1 lux). From wake-up time, they will
be subjected to either bright light (4000 lux) emitted by EnergyLights
((Philips Consumer Lifestyle B.V., Drachten) or dim light (10 lux). 1,5 hr
after lights on subjects will consume a standard 600 kcal liquid meal
(EnsurePlus). Blood samples will be obtained at regular intervals until 240 min
after the meal. Resting energy expenditure (REE) wille be performed 3.5 hrs
after breakfast. An adipose tissue biopsy will be obtained 4 hrs after the
meal.
Study burden and risks
Total study duration is three weeks. Participants will visit the Academic
Medical Center five times: three short visits (<1hr) and two 14hr admissions.
At study entry, patients will undergo physical examination and one blood sample
will be obtained. Participants will record sleep-wake times in a diary for five
days. Prior to each admission they will wear an actiwatch to verify adherence
to a stable sleep-wake rhythm. During each admission, participants will sleep
for one night at 1 lux in the experimental room. They will remain undisturbed
during this night. In the morning blood samples will be obtained from an
indwelling canula in a peripheral arm vein. Total amount of blood obtained
during the study will be 210 ml (100 ml at each admission and 10 ml at study
entry). Subcutaneous fat biopsies from the periumbilical region will cause
minor discomfort and a subcutaneous hematoma that will resolve over time.
Subcutaneous adipose tissue biopsies have negligible risks of infection or
haemorrhage. Use of EnergyLights may cause minor temporal complaints such as
headache or tired eyes. The 400 ml (600 kcal) Ensure Plus breakfast may for
some people be above the average breakfast size. This may cause a transient
sense of fullness.
Patients will receive a financial compensation of 200 euros and travel
expenses.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
- age 18-50 years
- male sex
- BMI 18-25
- fasting plasma glucose < 5.6 mmol/L
- habitual wake-up time between 7:00 and 9:00
Exclusion criteria
- medication interfering with glucose metabolism or neuronal synaptic transmission (corticosteroids, anti-depressants, anti-epileptic medication, other psychotropic drugs, anti malarials)
- gastro-intestinal or metabolic disease that will interfere with digestion or metabolism
- neuropsychiatric illness including severe depression
- epilepsy
- hypertension
- ophthalmological abnormalities
- lactose intolerance
- soy allergy
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL42188.018.12 |